Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Provided By PR Newswire

Last update: Jul 3, 2024

Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes

BETHESDA, Md., July 3, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax^® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024.